Structured page family:Cost guide

Teduglutide Cost Guide: Insurance, Cash Pay, and Savings

In the United States, Teduglutide costs depend on brand, pharmacy, insurance design, and whether the patient qualifies for manufacturer savings programs.

Active Market
This page is designed for US treatment decisions and uses US-first pricing and savings sources.
Official pricing
Verify current pricing directly on official Gattex pages before starting, because list pricing, self-pay offers, and eligibility terms can change.
Cash-pay reality
Official cash-pay pricing varies by pharmacy and dose. Contact multiple pharmacies or use a prescription discount service for current rates.
Insurance coverage
Commercial coverage for Teduglutide varies by plan and indication. Prior authorization is commonly required.
Savings and coupons
Manufacturer savings programs may reduce out-of-pocket cost for eligible commercially insured patients.
Prior Authorization
Prior authorization is common and may require documentation of diagnosis, prior treatments, and clinical need.

Price Breakdown

List price (monthly)
~$25,000-$35,000/month
Average wholesale price
~$23,000-$33,000/month
Pharmacy acquisition estimate
~$22,000-$30,000/month
Typical negotiated rate
~$18,000-$25,000/month
Price per dose
~$833 per 5 mg vial (0.05 mg/kg daily)
Annual cost at list price
~$300,000-$420,000

Pharmacy Price Comparison

PharmacyPrice RangeNotes
Specialty pharmacy$25,000-$35,000/monthREMS-required distribution

Insurance Coverage Landscape

Commercial plans
~80-90% with SBS diagnosis and REMS
Medicare Part D
Covered as specialty
Medicaid
Most states cover with extensive documentation
VA coverage
Case-by-case
TRICARE
Case-by-case
Employer plan typical tier
Tier 5 specialty; max out-of-pocket often applies

Prior Authorization Guide

Required Documentation
  • Short bowel syndrome diagnosis
  • Parenteral nutrition dependence
  • Stable clinical status
  • REMS enrollment
  • GI specialist attestation
Common Denial Reasons
  • Insufficient SBS documentation
  • Not PN-dependent
  • REMS not completed
  • Unstable condition
Appeal Template Points
  • FDA-approved for SBS
  • PN-dependent
  • REMS enrolled
  • GI specialist managing
  • Cost offset by reduced PN costs
Expected timeline: 2-4 weeks

Savings Programs and Patient Assistance

Gattex OneSource
manufacturer
Eligibility: All patients
Savings: Navigation and copay support
Income limit: None
Enrollment: moderate
Takeda program coordinates insurance and PAP
Takeda PAP
manufacturer
Eligibility: Uninsured/underinsured
Savings: May provide at reduced or no cost
Income limit: Case-by-case
Enrollment: complex
Requires extensive documentation

Generic and Biosimilar Status

No generic currently available
Expected: No generic expected

Cost by Dose

Dose/RegimenMonthlyAnnual
0.05 mg/kg daily$25,000-$35,000$300,000-$420,000

Annual Cost Projection

Year 1
$0-$420,000
Year 2
$0-$420,000
Year 3
$0-$420,000
Assumptions
  • Ultra-rare indication
  • PN cost offset significant

Cost-Saving Strategies

  • 1.Gattex OneSource is essential for insurance navigation
  • 2.Document PN volume and costs to demonstrate cost offset
  • 3.REMS enrollment must be completed before dispensing
  • 4.Explore foundation assistance if insurance gaps remain

International Price Comparison

CountryPrice RangeNotes
UKNHS specialized commissioningCase-by-case funding

Need help comparing teduglutide paths?

Use the provider matcher to package treatment interest, insurance, budget, urgency, and state context before you commit to a prescribing path.

Find a teduglutide provider
Trust Summary
Reviewed 2026-04-27 by PeptideScholar editorial review. This page currently cites 2 official sources.
Pricing, savings eligibility, and coverage rules can change quickly. Verify all current figures and terms directly on official brand pages before acting.

Teduglutide Cost FAQ

Sources

  1. 1. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients.
    Gut • 2005
    Claim type: clinical
    View source →
  2. 2. FDA Information on Teduglutide
    FDA • 2026
    Claim type: regulatory
    View source →

This content is for informational purposes only and does not constitute medical advice.